Cargando…
A novel small molecule glycolysis inhibitor WZ35 exerts anti-cancer effect via metabolic reprogramming
BACKGROUND: Liver cancer is the fifth leading cause of cancer death worldwide, but early diagnosis and treatment of liver cancer remains a clinical challenge. How to screen and diagnose liver cancer early and prolong the survival rate is still the focus of researchers. METHODS: Cell experiments were...
Autores principales: | Wang, Lihua, Zhu, Zheng, Liang, Qi, Tao, Yecheng, Jin, Gaowei, Zhong, Yaoyao, Dai, Jichen, Dai, Ruixia, Wang, Zhixiang, Chen, Junbo, Zhou, Lingjie, Ke, Shouyu, Zheng, Bin, Lan, Linhua, Lin, Xiaokun, Chen, Tongke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673307/ https://www.ncbi.nlm.nih.gov/pubmed/36401321 http://dx.doi.org/10.1186/s12967-022-03758-0 |
Ejemplares similares
-
Curcumin derivative WZ35 inhibits tumor cell growth via ROS-YAP-JNK signaling pathway in breast cancer
por: Wang, Lihua, et al.
Publicado: (2019) -
Identification of three metabolic subtypes in gastric cancer and the construction of a metabolic pathway-based risk model that predicts the overall survival of GC patients
por: Chen, Tongzuan, et al.
Publicado: (2023) -
Curcuminoid WZ35 synergize with cisplatin by inducing ROS production and inhibiting TrxR1 activity in gastric cancer cells
por: He, Wei, et al.
Publicado: (2019) -
ATLAS WZ Physics
por: Blumenschein, Ulla
Publicado: (2010) -
The TRPM7 channel reprograms cellular glycolysis to drive tumorigenesis and angiogenesis
por: Wu, Wanzhou, et al.
Publicado: (2023)